Viatris Views Ophthalmology, Dermatology, and Gastroenterology as Future Pipeline Focus

Equity Analyst

Keonhee Kim

Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris is one of the largest generic drug manufacturers in the world. Viatris' generics business makes up roughly 40% of company's sales and, along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin 

headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. 

Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Viatris. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

The remaining 60% of Viatris’ sales is derived from off-patent branded drugs, including Lipitor, Lyrica, and Norvasc. While macrotrends like the aging population and growing emerging markets can continue to boost sales, we still expect low- to mid-single-digit erosion in the business from pricing and volume headwinds driven from more patients opting generic versions. To combat this, Viatris has identified ophthalmology, dermatology, and gastroenterology as three key therapeutic areas of focus for future innovations. Since these areas are all specialty-driven, a small salesforce can capture a large number of doctors. And a lot of innovations usually come from smaller players, meaning there is not one big leader that Viatris has to displace to gain shares. It launched Tyrvaya, the first and only nasal spray 

for the treatment of dry eye disease at the time of launch, and it expects additional products for dry eye disease going forward. In 2023, it acquired Oyster Point and Famy Life Sciences, two companies that focus on ophthalmology, and we expect additional small tuck-in acquisitions in the three therapeutic areas to fuel its pipeline.

Business Strategy & Outlook

We assign Viatris a no-moat rating because we do not believe the company possesses any structural advantages strong enough to earn excess returns and generate return on invested capital above its cost of capital over the next 10 years. 

While generic drugs were around in the U.S. since the early 20th century, their industry experienced a significant growth following the passage of the 1984 Hatch-Waxman Act. The legislation facilitated the drug application process for generic drug manufacturers by providing them a safe harbor from patent infringement litigation from branded drug manufacturers and allowed the U.S. Food and Drug Administration to approve applications for generic drugs with abbreviated new drug applications. An ANDA requires the applicant to demonstrate its generic drug’s pharmaceutical equivalence and bioequivalence to the reference drug, but it generally does not require preclinical and clinical data to prove safety and effectiveness since it relies on the FDA’s prior approval of the reference drug’s safety and effectiveness. Overall, this legislation paved a much swifter way for generics manufacturers to get their drugs approved compared with a new drug application, which a new branded drug must go through.

The U.S. generic drug industry enjoyed another boost when Congress enacted a series of amendments named the Generic Drug User Fee Amendments (first one passed in 2012, second in 2017 and the latest in 2022), allowing the FDA to collect fees from ANDA applicants to expedite application approval process. The fees (an ANDA fee rate for 2023 was around $240,000) are not meaningful to sway big generic manufacturers away and they also provide additional revenue streams and financial support to the FDA, allowing applications to be approved more quickly and efficiently. 

These regulatory pushes by the U.S. government paved ways for the industry to be highly competitive and be filled with commoditized products, eroding a lot of pricing power that generics manufacturers once had. And although there are a few number of players that make up a relatively healthy share of the generics market, barriers to entry here is quite low, expanding possibilities for firms in the space to face additional competition going forward. This explains the hike in generic dispensing rate (percentage of prescriptions dispensed with a generic rather than a branded reference drug) which grew from 54% to 91% between 2002 and 2019. And while an average of less than 300 ANDAs were approved annually from 1985 to 2012, thanks to these changes, the FDA has averaged around 1,000 ANDA approvals per year over the last five years. 

Beyond government actions, generics manufacturers also face pressures from players within the drug supply chain. The formation of powerful generic sourcing groups and establishment of generic formularies by pharmacy benefit manager enabled drug distributors and drug buyers to effectively negotiate lower generic prices, hurting manufacturers’ margins.

Three large generic sourcing programs that were formed as joint ventures between large wholesalers and drug purchasers—ClarusONE (2016, McKesson and Walmart); Red Oak Sourcing (2013, Cardinal Health and CVS); and Walgreens Boots Alliance Development (2012, AmerisourceBergen and Walgreens)—have acted as additional headwind for generics manufacturers. These entities were created to lower generics acquisition costs through the aggregation of purchasing power and as a result, they can demand higher buy-side discounts and rebates from generics manufacturers, ultimately eating into their profits. They now purchase roughly 80% of all generics sold in the U.S. Additionally, the interchangeability between generics has facilitated the establishment of generic formularies, in which wholesalers can use their purchasing scale to negotiate deeper concessions for placement in the generic sourcing program. As these three players continue to make up a larger portion of generic sourcing in the country and enhance their buying power, generics manufacturers are left with no other choice but to face the burden, resulting in low- to mid-single-digit price erosion in the market year over year.

By our estimate, roughly 40% and 50% of Viatris total sales are derived from generics and off-patent branded drugs, respectively, and both areas are highly susceptible to all the pricing headwinds mentioned above. Viatris has decided to combat this by rationalizing and optimizing its portfolio, carefully deciding which drugs to continue commercializing and which drugs to discontinue. The company opted to exit spaces where it had too many existing players and discontinue small-molecule drugs that are fairly simple to be FDA-approved and to be replicated. Furthermore, Viatris has continued to pursue more opportunities into branded drugs, aiming to launch sizable novel drugs that can have a meaningful impact on the top and bottom lines. Viatris has also sought to expand its presence in complex generics. These drugs typically face limited competition due to a more complicated level of research and development required before reaching commercial stage. Instead of being available in simple oral tablets, which are relatively easy to replicate by competitors, complex generics and biosimilars usually come in injectables, inhalers, and other different forms that pose more challenges to other manufacturers to produce. 

Despite these efforts, we don’t believe Viatris has any structural advantages over other generic manufacturers. It doesn’t have a meaningfully larger number of first-to-file launches compared with other players in the space. And even if it launches a few drugs that are first to market and gain 180-day exclusivity periods in certain products, they are likely to face direct competition as soon as that period expires, leading to significant volume reductions. If Viatris continues to downsize its portfolio of commoditized and easy-to-replicate generic drugs and replace them with more innovative medicines, we could potentially revisit our analysis. For now, we do not believe Viatris earns a moat rating.

None

Economic Moat

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

From a technical perspective, Viatris Inc. (VTRS) is looking like an interesting pick, as it just reached a key level of support. VTRS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross

Canadian Imperial Bank of Commerce

Elevance Health Inc

Hormel Foods

Target

Vanguard Dividend Appreciation ETF

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

The stock market, specifically the S&P 500, is still lurking over 4,400, up 16% this year. UPS is projecting to earn between $85 billion to $100 billion in revenue, just large amounts, even during a tough year that we have all been through. Similar to UPS, CM is getting crushed, down almost 9% in the last month and officially below the $40 mark.

Dividend Stock Watch List: Lanny's September 2023 Edition

Takeda Pharmaceutical

One of these high-yield pharma stocks stands out as a better buy right now.

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc. (NASDAQ: VTRS) on behalf of long-term stockholders following a class action complaint that was filed against Viatris on May 15, 2023 with a Class Period from March 1, 2021 and February 25, 2022. Our investigation concerns whether the board of directors of Viatris have breached their fiduciary duties to the company. Throughout the.

VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous quarter but down 4.9% from the second quarter of 2022. Viatris' R&D spending was $207.9 million in Q2 2023, up 28.3% year-over-year due to increased investment in developing product candidates such as MR-148 and MR-141.

Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market

Viatris' near-term focus now is to reduce its heavy debt load. The company is also simplifying its business through more divestitures.

Where Will Viatris Be in 5 Years?

Viatris is trying to get its two generic versions of semaglutide approved for sale. Novo Nordisk is suing Viatris to prevent the approval from happening.

Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?

CVS Health

CVS Health's diversified business will help it rebound from recent issues in the long run. Viatris is making important changes to its operations that should yield benefits down the road.

2 Beaten-Down Dividend Stocks to Buy

Viatris reported strong second-quarter earnings, beating estimates on both revenue and earnings per share. The company showed signs of sales growth on a divestiture adjusted basis and is on track for $500 million of new product revenue. Management is committed to 9% of shareholder returns through dividends and buybacks, which can create momentum going into 2024.

Viatris: Turning Point For Cheap Pharma Stock

Viatris is paying down its debt and planning to return capital to shareholders too. The generic drugmaker's growth hasn't been very impressive so far.

Is Viatris Stock Good for Dividend Income?

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say

Viatris shares advanced after the drugmaker posted better-than-expected results, said it will announce one or more divestitures this quarter, and indicated the FDA agreed to consider approval of its new multiple sclerosis treatment produced with Israel's Mapi Pharma.

Viatris Shares Gain on Sales, Divestitures, and FDA Review of Its MS Drug

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

Viatris Inc. (NASDAQ:VTRS ) Q2 2023 Earnings Call Transcript August 7, 2023 8:30 AM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Jeff Nau - Eye Care Division Conference Call Participants Glenn Santangelo - Jefferies Jason Gerberry - Bank of America Ash Verma - UBS David Amsellem - Piper Sandler Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Operator Good morning. My name is Todd, and I will be your conference operator today.

Viatris Inc. (VTRS) Q2 2023 Earnings Call Transcript

Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.88 per share a year ago.

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

Viatris Inc beat Wall Street estimates for second-quarter revenue on Monday, on the strength of its branded drug portfolio, sending its shares up 2% in premarket trading.

Viatris beats second-quarter revenue estimates, says divestiture plans on track

Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the Quarter Strong Results Signal Expected Beginning of Growth Journey Reaffirms that Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow Expected to be at Midpoint of 2023 Guidance Ranges[1] Pays Down $727 Million of Debt Year to Date Remains on Track to Announce Planned Divestitures in 2023 Board of Directors Declares Quarterly Dividend of $0.12 per Share PITTSBURGH , Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today reported another strong quarter of operating results which continues to set the Company up well as it prepares to bring its Phase 1 strategy to an end and position itself for a strong beginning of Phase 2 in 2024 and beyond. Executive Commentary Viatris CEO Scott A.

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and continued commitment toward addressing the unmet needs of the MS community PITTSBURGH and NESS ZIONA, Israel , Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the companies' recently submitted New Drug Application (NDA) for GA Depot 40 mg.

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

Viatris is an appealing stock for dividend investors. Its business model should be sufficient to deliver long-term growth.

Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years

Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.

Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?

Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P.

Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva

Pfizer

Dividend investing happens, whether the stock market is up or down, whether the Fed raises interest rates or lowers. The stock market, specifically the S&P 500, is back above 4,500.

Dividend Stock Watch List: Lanny's August 2023 Edition

Carnival

Cronos Group

iShares MSCI Emerging Markets ETF

Edwards Lifesciences

Kopin

Oric Pharmaceuticals

Principal Financial Group

Prudential Financial

SPDR S&P 500 ETF Trust

The stock market, as measured by the S&P 500 Index SPX, -0.64% ), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is a bit of an overbought condition, but not a sell signal.

You can still run with the stock market's bulls, but watch the exits

Investors like Viatris for its dividend and low valuation. Still, Viatris sales right now are on the decline.

Viatris Stock: Bull vs. Bear

Viatris offers investors a high dividend yield of 4.7%. The company's underlying business, however, has struggled to generate growth.

News for Viatris Stock (VTRS)